EKSO BIONICS HOLDING (OTCBB:EKSO) disclosed that Amy Wendell has been elected to its Board. Prior to the new role, she was associated with Covidien plc (NYSE:COV) and looked after the “Strategy and Business Development.” Nathan Harding, the CEO said Wendell concluded several acquisitions successfully in past.

The ratings

Zacks firm issued a report on Ekso and reaffirmed a ‘hold’ rating on EKSO stock. The research firm stated that the company is operational in the industry of wearable robots or exoskeletons used in the field of military, medical, consumer and industrial markets. The operating segment included Medical and Engineering services segment. It operates in South Africa, the Middle East, Western Europe and North America regions with its headquarter in Richmond, California.

The momentum

Ekso Bionics declined more than 1% on Friday’s trading session, hitting $1.62. The decline came at a share volume of 227,550 compared to average share volume of 965,122. The stock has a one year high of $1.13 and a one year low of $0.75. The market capitalization stands at $165.03 million.

The performance

Ekso Bionics released its latest quarterly financial numbers on Tuesday, March 17, 2015. The company posted ($0.06) earnings a share for the quarter, lower than the analysts’ consensus guidance of ($0.03) by $0.03. The analysts expect the full year earnings to come at $-0.16 per share.

The analysts’ view

There are many other research analysts who have also issued reports on EKSO stock. The analysts at Sterne Agee CRT released a report on stock of Ekso Bionics Holding on Wednesday, March 25, 2015. They have a “buy” rating on the stock with a price target of $1.75 per share. Separately, experts at Ladenburg Thalmann issued coverage on Ekso stock in a research note on March 5, 2015. They have a “buy” rating on the stock with a price target of $3.50 per share.